Relief Reports that its U.S. Collaboration Partner NRx Pharmaceuticals has Filed a New Breakthrough Therapy Designation Request for Aviptadil
Relief Therapeutics Reports that NRx Pharmaceuticals has Filed a New Breakthrough Therapy Designation Request for Aviptadil
Relief Therapeutics reported, on Friday, that NRx Pharmaceuticals has announced that it has filed a new Breakthrough Therapy Designation request with the U.S. Food and Drug Administration (“FDA”) for Relief’s drug candidate, RLF-100® (aviptadil).NRx Pharmaceuticals is the parent company of Relief’s collaboration partner NeuroRx (for aviptadil).
According to NRx, the request was based on a post-hoc analysis, focused on a subgroup of patients with Critical COVID-19 that, in addition to aviptadil or placebo, were also treated with remdesivir and whose respiratory failure due to Critical COVID-19 continued to progress.
Relief’s drug candidate, RLF-100® (aviptadil) is a synthetic form of Vasoactive Intestinal Peptide (VIP), is in late-stage clinical testing in the U.S. for the treatment of respiratory deficiency due to COVID-19 through Relief’s collaboration partner in the U.S., NeuroRx, Inc.